HB 209 would create a new section of Maryland health law governing assisted reproductive treatment, including in vitro fertilization, insemination, embryo transfer, and related procedures. The bill requires health care providers to obtain separate written informed consent from both donors and recipients before using human reproductive material, and it specifies that consent must be documented and retained in patient records. It also requires providers to use donor material only in a manner consistent with the donor’s consent and to inform recipients of any misuse, misrepresentation, or error involving the reproductive material used in treatment.
The bill further prohibits a provider from knowingly or intentionally using the provider’s own sperm or ovum in assisted reproductive treatment without the patient’s informed consent, and it bars providers from using donor material without the donor’s consent or contrary to that consent. It also makes it unlawful for providers or their employees to misrepresent the quality of reproductive material or information about a donor’s identity, genetic characteristics, or medical history. Civil remedies would be available to affected patients, spouses or domestic partners, children born from the treatment, and donors, including damages, attorney’s fees, and in some cases access to medical records; a separate felony penalty would apply to intentional or knowing use of a provider’s own reproductive material without consent.
The bill’s impact on state law would be to add explicit informed-consent, disclosure, reporting, and liability rules for assisted reproductive services under the Health – General Article. It would create new causes of action, set filing deadlines, authorize liquidated and compensatory damages, and establish criminal liability for the most serious misconduct. In practice, it would affect fertility clinics, reproductive endocrinologists, embryology and lab staff, donors, recipients, and children born through assisted reproduction by imposing stricter documentation and compliance obligations.
Because there were no committee transcripts or recorded votes provided, there is little direct evidence of legislative debate or public sentiment in the available record. The only clear procedural signal is that the bill was withdrawn by the sponsor in the House, which suggests it did not advance to a recorded vote. Based on the bill text alone, the measure appears aimed at preventing reproductive fraud and unauthorized use of genetic material, but the withdrawal means there is no documented floor or committee consensus to gauge broader support or opposition.
The main points of contention likely center on the scope of liability, the felony penalty, and the bill’s private right of action, especially the ability of children and donors to sue years after treatment. Potential concerns also include how clinics would verify consent, how errors or misrepresentations would be distinguished from intentional misconduct, and whether the bill could increase litigation or compliance costs for fertility providers. Supporters would likely emphasize patient autonomy, donor protection, and transparency in assisted reproduction.
HB 209 would amend the Maryland Health – General Article by adding Section 20–112 to regulate assisted reproductive treatment. It would impose new informed-consent requirements, prohibit unauthorized use of a provider’s or donor’s reproductive material, require disclosure and reporting of misuse or misrepresentation, and create civil and criminal penalties. The bill would directly affect fertility clinics, health care providers authorized to perform assisted reproductive treatment, donors, recipients, and children born through such treatment.
No committee discussion or vote record is available, and the bill was withdrawn by the sponsor in the House before further action. As a result, the public legislative sentiment cannot be measured from recorded debate. The bill’s text suggests a policy goal of protecting patients and donors from reproductive fraud and unauthorized use of genetic material, which would likely appeal to supporters of stronger consent protections, while also raising concerns among providers about liability and compliance burdens.
The most likely areas of contention are the bill’s broad civil liability provisions, the felony penalty for intentional or knowing misuse of a provider’s own sperm or ovum, and the long limitations periods for bringing claims. Another likely dispute is whether the bill gives sufficient flexibility for inadvertent errors versus intentional misconduct, and whether the reporting and disclosure duties could be operationally burdensome for fertility clinics. Supporters would likely focus on informed consent, donor autonomy, and preventing deception in assisted reproduction, while opponents or cautious stakeholders would likely emphasize litigation exposure, recordkeeping burdens, and the risk of criminalizing clinical conduct.